What is EvoEndo?
Founded in 2017, EvoEndo operates at the intersection of gastroenterology and digital health. The company specializes in the development of sterile, single-use flexible endoscopes designed to facilitate procedures without the need for traditional sedation. By integrating virtual reality-based patient distraction, EvoEndo effectively mitigates the physiological and psychological stressors associated with endoscopic examinations. This dual-modality strategy—combining hardware innovation with immersive therapeutic software—addresses a critical gap in outpatient care, aiming to reduce procedural costs and improve patient recovery times. As a preclinical stage entity, the firm is currently leveraging its capital to refine its proprietary systems and navigate the complex regulatory pathways required for widespread clinical adoption.
How much funding has EvoEndo raised?
EvoEndo has raised a total of $18.5M across 2 funding rounds:
Private Equity
$10.1M
Series A
$8.4M
Private Equity (2021): $10.1M, investors not publicly disclosed
Series A (2022): $8.4M led by TLP Investment Partners and Sunshine Charitable Foundation
Key Investors in EvoEndo
TLP Investment Partners
A private investment firm focused on providing growth capital to innovative companies within the healthcare and life sciences sectors.
Sunshine Charitable Foundation
A mission-driven organization that supports advancements in medical research and patient care technologies to improve public health outcomes.
Undisclosed Investor
An institutional investor participating in the funding round to support the long-term commercialization of medical device technologies.
What's next for EvoEndo?
With the recent infusion of capital, EvoEndo is poised to accelerate its research and development pipeline, focusing on the scalability of its single-use endoscope manufacturing and the expansion of its VR distraction platform. The company's strategic roadmap involves transitioning from preclinical validation to human clinical trials, a critical phase for establishing efficacy and safety profiles. Investors are closely monitoring the firm's ability to disrupt the traditional endoscopy market, where the shift toward sedation-free, cost-effective alternatives is gaining momentum. Future growth will likely hinge on successful regulatory clearances and the establishment of strategic partnerships with major healthcare providers seeking to optimize their outpatient procedural workflows.
See full EvoEndo company page
